Collaboration develops new imaging protocol
Imaging protocol assesses molecular mechanism of work in the treatment of deadly childhood cancer neuroblastoma.
Showing 121 - 140 of 205 results
Imaging protocol assesses molecular mechanism of work in the treatment of deadly childhood cancer neuroblastoma.
See details of previously published customer updates from our Health products team.
The new Micro Computed Tomography (MCT) beamline is the first instrument to become operational as part of the $94 million Project BRIGHT program, which will see the completion of eight new beamlines at ANSTO’s Australian Synchrotron.
This joint initiative at ANSTO has developed a new capability: solid surface radiolabelling to evaluate Auger emitting sources for next-generation targeted therapy.
ANSTO is working with government partners to ensure that radioactivity in drinking water supplied to Aboriginal communities is at levels considered safe for consumption.
International neutron scattering award for retired head of former Bragg Institute, Prof Robert Robinson
Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer is now available in Australia
The Imaging and Medical beamline (IMBL) is a flagship beamline of the Australian Synchrotron built with considerable support from the NHMRC. It is one of only a few of its type, and delivers the world’s widest synchrotron x-ray ‘beam’.
Thirty years of ANSTO's unique capability in monitoring fine particle pollution provides insight on bushfire smoke.
Cyclotek and ANSTO have announced the launch of a Joint Venture (JV), to establish Australia’s first GMP (Good Manufacturing Practice) theranostics facility starting in Melbourne, Australia.
Doping with transition metals produced stability in bismuth oxide.
Doping with transition metals produced stability in bismuth oxide.